🇺🇸 FDA

Intelligence · Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
20,548
Companies
1,769
Drugs tracked
4,797

Quick answer

NovaPharmaNews tracks 20,548 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.

2,153 results for “Ou” Clear

  1. TAK-676

    Takeda

    Head and Neck Squamous Cell Carcinoma

    phase 1 small molecule completed

    1 trial

  2. TD-1607

    Theravance Biopharma Ireland Umited

    Serious Infections Due to Known or Suspected Gram-positive Pathogens

    phase 1 small molecule completed

    1 trial

  3. TGD001 SAD study in healthy volunteers

    Lacuna Pharma Pty Ltd

    A Phase I randomized, double-blind, placebo-controlled study to assess the safety and pharmacokinetics of single-ascending doses of TGD001 in healthy volunteers

    phase 1 other active

    1 trial

  4. TP-05 (lotilaner oral), fasted group

    Tarsus Pharmaceuticals

    Healthy

    phase 1 small molecule completed

    1 trial

  5. TQB2825 Injection (Subcutaneous Injection)

    Shanghai University of Traditional Chinese Medicine

    CD20-positive Hematological Malignancies

    phase 1 small molecule active

    1 trial

  6. TQF3250 placebo

    Chia Tai Tianqing Pharmaceutical Group Co.,

    Hyperglycemia

    phase 1 small molecule active

    1 trial

  7. Tafamidis round 2, Tafamidis round 1, Tafamidis oblong

    Pfizer Australia Pty Ltd

    aransthyretin amyloid cardiomyopathy

    phase 1 small molecule active

    1 trial

  8. The 10mg dose group

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Healthy Volunteers

    phase 1 small molecule completed

    1 trial

  9. The CALiPSO-1 Study: A Study of CNTY-101, a CD19-targeted CAR iNK Cell Product, in Participants with Refractory B cell-mediated Autoimmune Diseases

    Century Therapeutics

    systemic lupus erythematosus [SLE]/lupus nephritis [LN], idiopathic inflammatory myopathy [IIM], and diffuse cutaneous systemic sclerosis [DcSSc]

    phase 1 other active

    1 trial

  10. The goal of this clinical study is to learn more about the safety and dosing of the study drugs, KITE-363 and KITE-753, in participants with relapsed and/or refractory B-cell lymphoma.

    Lacuna Pharma Pty Ltd

    Relapsed and/or Refractory B-cell Lymphoma

    phase 1 other active

    1 trial

  11. The pivotal bioequivalence study comparing the test product to the reference product, which belong to the group of medicines used in the treatment of type 2 diabetes mellitus when the condition cannot be adequately controlled by diet and exercise alone.

    Lacuna Pharma Pty Ltd

    Not applicable (submitted trial is a BE study in healthy subjects).

    phase 1 other active

    1 trial

  12. The pivotal bioequivalence study comparing the test product to the reference product, which belong to the group of medicines used in treatment of uncomplicated lower urinary tract infections.

    Sciencepharma Sp. z o.o

    Not applicable (submitted trial is a bioequivalence in healthy subjects)

    phase 1 other active

    1 trial

  13. The pivotal bioequivalence study comparing the test product to the reference product, which belongs to the group of medicines used in treatment and prevention of Influenza.

    Lacuna Pharma Pty Ltd

    influenza

    phase 1 other active

    1 trial

  14. The pivotal bioequivalence study comparing the test product to the reference product, which belongs to the group of medicines used in treatment of schizophrenia in adult patients.

    Lacuna Pharma Pty Ltd

    Not applicable (submitted trial is a BE study in healthy subjects).

    phase 1 other active

    1 trial

  15. The pivotal bioequivalence study comparing the test product to the reference product, which belongs to the group of medicines used in treatment of schizophrenia in adults patients.

    Lacuna Pharma Pty Ltd

    Bioequivalence study under fasting conditions

    phase 1 other active

    1 trial

  16. The pivotal bioequivalence study comparing the test product to the reference product, which belongs to the group of medicines used in treatment of type 2 diabetes mellitus in adults and children aged 10 years and above, and heart failure and chronic kidney disease in adults patiens.

    Lacuna Pharma Pty Ltd

    Not applicable (submitted trial is a BE study in healthy subjects.

    phase 1 other active

    1 trial

  17. Treatment of cancer with Immune Checkpoint Inhibition therapy boosted by High Intensity Focused Ultrasound Histotripsy (the iFOCUS study)

    Disc Medicine

    Metastatic or unresectable solid malignancies. Standard of care treatment options must not be available or not be considered feasible. Patients must have a primary tumor or metastasis that is suitable for HIFU-HT treatment.

    phase 1 other active

    1 trial

  18. Trial of the novel peroral anti-tumor treatment in patients with solid tumors

    Lacuna Pharma Pty Ltd

    Metastatic or locally advanced solid tumors for which no standard therapy exists or standard therapy has failed: tumors of lung, head and neck, colon, stomach, esophagus, breast, ovary and/or fallopian tube or primary peritoneal high-grade serous carcinoma

    phase 1 other active

    1 trial

  19. UB-221

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Chronic Spontaneous Urticaria

    phase 1 mab active

    1 trial

  20. UTAA91 injection

    Suzhou Ribo Life Science Co.

    Rheumatoid Arthritis (RA)

    phase 1 mab active

    1 trial

  21. VEGF inhibitor PTC299

    PTC THERAPEUTICS, INC.

    Brain and Central Nervous System Tumors

    phase 1 small molecule completed

    1 trial

  22. VV261 5mg group

    Vigonvita Life Sciences

    Healthy Volunteers

    phase 1 small molecule active

    1 trial

  23. VX15/2503

    VACCINEX, INC.

    Squamous Cell Carcinoma of the Head and Neck

    phase 1 mab active

    1 trial

  24. Valemetostat Tosylate, DS-8201a, Datopotamab deruxtecan, Valemetostat Tosylate, Valemetostat Tosylate

    Daiichi Sankyo

    This study will be a Phase 1b, global, multicenter, open-label, 2-part study of valemetostat in combination with DXd ADCs. The Master Protocol study design contains independent subprotocols, which have been defined by treatment combination and subject population, as follows: Sub-protocol A: Valemetostat in combination with T-DXd in subjects with previously treated, unresectable and/or metastatic HER2-low (immunohistochemistry[IHC] 1+ or IHC 2+/in situ hybridization [ISH]-negative) BC; for details, see Sub-protocol A. Sub-protocol B: Valemetostat in combination with T-DXd in subjects with previously treated, advanced or metastatic HER2-positive gastric or GEJ adenocarcinoma; for details, see Sub-protocol B. Sub-protocol C: Valemetostat in combination with Dato-DXd in subjects with previously treated, locally advanced, unresectable, or metastatic non-squamous NSCLC with or without actionable genomic alteration(s); for details, see Sub-protocol C.

    phase 1 small molecule active

    1 trial

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 20,548 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources